Published in Am J Health Syst Pharm on December 01, 2016
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost (2007) 3.38
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52
Pharmacogenomics: "noninferiority" is sufficient for initial implementation. Clin Pharmacol Ther (2011) 2.43
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost (2008) 1.62
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet (2014) 1.57
The IGNITE network: a model for genomic medicine implementation and research. BMC Med Genomics (2016) 1.17
Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy (2013) 1.09
Implementation of a pharmacogenomics service in a community pharmacy. J Am Pharm Assoc (2003) (2014) 1.00
Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy (2014) 0.96
Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. Pharmacogenomics (2014) 0.96
Advancing Pharmacogenomics as a Component of Precision Medicine: How, Where, and Who? Clin Pharmacol Ther (2015) 0.82
Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. Drugs (2015) 0.79